The association between germline <scp><i>BRCA2</i></scp> variants and sensitivity to platinum‐based chemotherapy among men with metastatic prostate cancer

Abstract

BRCA2-associated, castration-resistant prostate cancer is associated with a higher likelihood of response to carboplatin-based chemotherapy than non-BRCA2-associated prostate cancer. Cancer 2017;123:3532-9. © 2017 American Cancer Society.